Fresenius Kabi to Buy Ivenix for $240M

Fresenius Kabi has agreed to buy specialized infusion therapy firm Ivenix. The purchase price will be a combination of $240 million up front and milestone payments.
 
Ivenix develops a technologically advanced infusion system that includes a large volume pump (LVP) with administration sets, infusion management software tools, applications, and analytics. The system is designed to minimize infusion-related errors and lower total cost of ownership.
 
The Ivenix infusion system launched late last year after receiving U.S. Food and Drug Administration (FDA) approval. Combining Ivenix’s hardware and software products with Fresenius Kabi’s intravenous fluids and infusion devices will create a comprehensive portfolio.
 
Fresenius Kabi also agreed to acquire 55% stake in biopharma company mAbxience for 495 million Euros upfront and milestone payments. Fresenius will broaden its biosimilars portfolio and gain three facilities for biologic drug substance production.
 
Both deals are expected to close by mid-2022.
 
“Expanding our MedTech business and broadening our presence in Biopharmaceuticals are key to our Vision 2026 program,” Fresenius Kabi CEO Michael Sen told the press. “These announcements fit squarely into our plans. With the acquisition of Ivenix, we add the next generation infusion therapy platform; we complement and strengthen our existing infusion therapy offering and we create a superior portfolio for the U.S. market. With mAbxience, we are making a step-change in our biopharmaceuticals profile. This is a highly complementary transaction in terms of biologics pipeline, manufacturing capabilities and the business model. mAbxience is two businesses in one company. mAbxience and Ivenix as portfolio advancements are good for patients, good for healthcare providers and our company.”
 
Stephan Sturm, CEO of Fresenius, said: “Through these acquisitions we are further strengthening and leveraging Fresenius Kabi’s position, as both perfectly complement the company’s growth businesses in biopharmaceuticals and medical technology. We will continue allocating capital in a targeted manner to rigorously pursue the recently presented growth strategy of our health care Group which has defined Fresenius Kabi as top priority. In this way, we are creating even better conditions for providing ever better medicine to ever more people. At the same time, we create meaningful value for our shareholders.”